Shanghai Haohai Biological Technology Co. Ltd (5HB) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Shanghai Haohai Biological Technology Co. Ltd (5HB) has a cash flow conversion efficiency ratio of 0.023x as of June 2023. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (€141.99 Million ≈ $166.00 Million USD) by net assets (€6.09 Billion ≈ $7.12 Billion USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Shanghai Haohai Biological Technology Co. Ltd - Cash Flow Conversion Efficiency Trend (2016–2024)
This chart illustrates how Shanghai Haohai Biological Technology Co. Ltd's cash flow conversion efficiency has evolved over time, based on yearly financial data. Read how much debt does Shanghai Haohai Biological Technology Co carry for a breakdown of total debt and financial obligations.
Shanghai Haohai Biological Technology Co. Ltd Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Shanghai Haohai Biological Technology Co. Ltd ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Cytogen Inc
KQ:217330
|
-0.059x |
|
ALM Equity AB (publ)
ST:ALM
|
0.122x |
|
Tiong Nam Logistics Holdings Bhd
KLSE:8397
|
0.106x |
|
Méliuz S.A
SA:CASH3
|
0.012x |
|
Tipco Foods Public Company Limited
BK:TIPCO
|
-0.012x |
|
Ablerex Electronics Co Ltd
TWO:3628
|
0.104x |
|
Adverum Biotechnologies Inc
NASDAQ:ADVM
|
0.505x |
|
Cherry Hill Mortgage Investment Corp
NYSE:CHMI
|
0.035x |
Annual Cash Flow Conversion Efficiency for Shanghai Haohai Biological Technology Co. Ltd (2016–2024)
The table below shows the annual cash flow conversion efficiency of Shanghai Haohai Biological Technology Co. Ltd from 2016 to 2024. For the full company profile with market capitalisation and key ratios, see market cap of Shanghai Haohai Biological Technology Co.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | €5.92 Billion ≈ $6.92 Billion |
€648.57 Million ≈ $758.25 Million |
0.110x | +3.96% |
| 2023-12-31 | €6.02 Billion ≈ $7.03 Billion |
€634.45 Million ≈ $741.74 Million |
0.105x | +169.06% |
| 2022-12-31 | €5.90 Billion ≈ $6.90 Billion |
€231.30 Million ≈ $270.41 Million |
0.039x | -30.62% |
| 2021-12-31 | €6.06 Billion ≈ $7.09 Billion |
€342.29 Million ≈ $400.17 Million |
0.056x | +23.58% |
| 2020-12-31 | €5.73 Billion ≈ $6.70 Billion |
€262.07 Million ≈ $306.39 Million |
0.046x | -25.95% |
| 2019-12-31 | €5.65 Billion ≈ $6.61 Billion |
€348.91 Million ≈ $407.91 Million |
0.062x | -39.50% |
| 2018-12-31 | €3.84 Billion ≈ $4.48 Billion |
€391.28 Million ≈ $457.45 Million |
0.102x | +0.12% |
| 2017-12-31 | €3.37 Billion ≈ $3.94 Billion |
€343.06 Million ≈ $401.07 Million |
0.102x | +19.56% |
| 2016-12-31 | €2.99 Billion ≈ $3.49 Billion |
€254.49 Million ≈ $297.52 Million |
0.085x | -- |
About Shanghai Haohai Biological Technology Co. Ltd
Shanghai Haohai Biological Technology Co., Ltd. engages in the research, development, manufacture, and sale of biomedical materials in Mainland China, Europe, the United States, and internationally. The company offers ophthalmic implants, assistive devices, and medical devices; medical optical instruments, including intraocular lenses, endoscopic equipment, ophthalmic surgical instruments, and ot… Read more